Navigation Links
Blood Pressure Drugs Might Prevent Parkinson's
Date:2/6/2008

Preliminary study finds some benefit from calcium channel blockers

WEDNESDAY, Feb. 6 (HealthDay News) -- People taking calcium channel blockers to control their high blood pressure may find the regimen has a double benefit: Researchers say long-term use of the drugs also might cut the risk of developing Parkinson's disease.

But the findings are far from definitive and not yet ready for prime-time medical practice.

"There are not necessarily direct clinical implications, but the data support previous hypotheses that calcium channel blockers may have neuroprotective effects," said study senior author Christoph R. Meier, a clinical pharmacologist with University Hospital Basel, in Switzerland. "This may stimulate additional clinical and mainly basic research in this area."

The findings were published in the Feb. 6 online issue of Neurology, the medical journal of the American Academy of Neurology.

Parkinson's disease is a chronic, degenerative neurological disorder affecting at least one million people in the United States and six million people worldwide, according to the Michael J. Fox Foundation for Parkinson's Research. The condition involves the loss of brain cells that produce the chemical dopamine, resulting in movement problems including tremors.

Previous studies with rodents and primates had uncovered a possible "neuroprotective effect" from calcium channel blockers and angiotensin converting enzyme (ACE) inhibitors, another class of blood pressure medications, the researchers said.

The new study looked at the effect of calcium channel blockers, ACE inhibitors, AT II antagonists and beta blockers on the development of Parkinson's disease.

The study involved more than 7,000 men and women in the United Kingdom over the age of 40, half of whom had been diagnosed with Parkinson's and half of whom had not. Almost half the people in each group used blood pressure medications.

Participants currently taking calcium channel blockers lowered their risk of developing Parkinson's by 23 percent. There was no real effect for the other types of medications.

The strongest reduction in risk was seen in patients who had had 30 or more prescriptions filled and were still receiving prescriptions within 90 days prior to the diagnosis of Parkinson's, the researchers said.

Women tended to have more of a risk reduction than men but not if they had had less than 30 prescriptions filled. Individuals over the age of 80 had the most pronounced lowering of risk.

But even the study authors acknowledged that it's not clear where to go next with the findings.

"It may be desirable that basic research activities explore the effect of calcium channel blockers on the central nervous system which may lead (in theory) to new therapeutic strategies or even new drugs to prevent or treat Parkinson's," Meier said. "Regarding clinical or epidemiological/observational research, it would be nice if other research groups analyzed their databases and came up with their findings. They may either confirm our observations or come to the conclusion that our finding is isolated and that there is no need to further pursue this issue."

Dr. Ralph Sacco, professor and chair of neurology at the University of Miami Miller School of Medicine, agreed. "This is a tricky one. You don't know if there is a true association or not. There are potential problems with this type of analysis," he said.

But, Sacco pointed out, there is evidence accumulating on the relationship between Alzheimer's, another neurodegenerative disease, and circulatory system problems.

More information

Learn more about Parkinson's at the Michael J. Fox Foundation for Parkinson's Research.



SOURCES: Christoph R. Meier, Ph.D., clinical pharmacologist, Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland; Ralph L. Sacco, M.D., professor and chair of neurology, University of Miami Miller School of Medicine; Feb. 6, 2008, Neurology, online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed
2. Dangerous Condition Underscores Importance of Home Blood Pressure Monitoring
3. Cord Blood America Supports Trend From New York, California for States to Inform Parents of the Advantages of Umbilical Cord Blood Storage
4. Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
5. Research shows a daily does of beetroot juice can beat high blood pressure
6. Hospital Patients Blood Clot Risk High
7. Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder
8. Docs Should Tell All About Cord Blood Banks
9. Engineers use bloods hydrodynamics to manipulate stem, cancer cells
10. Genetics Influence Blood Pressure Medications
11. Liver Cancer Drug Raises Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blood Pressure Drugs Might Prevent Parkinson's
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Finn Mouseson”: ... take precedence in an average life. This mouse sets out on a journey that ... heart. “Finn Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, ...
(Date:9/20/2017)... ... ... “The Financial Favor of God; Second Edition”: a personal and exquisite recipe ... creation of published author, Brooks Rathell. , “We typically hear about the favor of ... financial favor of God. Not only does it exist, but it is meant for ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... MD (PRWEB) , ... September 19, 2017 , ... ... the Society of Professional Benefit Administrators (SPBA) hosted “Expanding Your Success” ... for SPBA Members as it focused on best practices for third party administrators ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... 7, 2017 Caris Life Sciences, a ... the promise of precision medicine, today announced results ... of its molecular profiling approach in guiding therapeutic ... profiling plus (CGP+) with Caris Molecular Intelligence ® ... a molecular level, leading to more therapeutic options ...
Breaking Medicine Technology: